Quarterly and annual results disclosed under 8-K Item 2.02.
W&T OFFSHORE INC reported financial results for the fourth quarter ended December 31, 2025.
“On March 16, 2026, W&T Offshore, Inc. (the “Company”) i ssued a press release reporting on final financial and operational results for the fourth quarter ended December 31, 2025.”
FutureFuel Corp. reported the year ended December 31, 2025 results: revenue $95.7 m illion, net income $49.4 m illion, EPS $1.13 per diluted share.
“● Revenues wer e $95.7 m illion, a decrease of 61% , or $147.6 million, compared to $243.3 million. ● Net loss wa s $49.4 m illion, or $1.13 per diluted share, down from net income of $15.5 million, or $0.35 per diluted share.”
FutureFuel Corp. reported the fourth quarter ended December 31, 2025 results: revenue $19.8 m illion, net income $12.0 m illion, EPS $0.27 per diluted share.
“● Revenues wer e $19.8 m illion, a decrease of 68% , or $41.7 million, compared to $61.5 million. ● Net loss wa s $12.0 m illion, or $0.27 per diluted share, down from net income of $2.8 million, or $0.06 per diluted share.”
GREEN DOT CORP reported the year ended December 31, 2025 results: revenue $2,080,491, net income $(98,866), EPS $(1.79).
“December 31, 2025 2024 % Change 2025 2024 % Change (In thousands, except per share data and percentages) GAAP financial results Total operating revenues $ 522,615 $ 455,024 15% $ 2,080,491 $ 1,723,876 21% Net (loss) income $ (46,823) $ 5,103 * $ (98,866) $ (26,702) 270% Diluted (loss) income per common share $ (0.84) $ 0.09 * $ (1.79) $ (0.50) 258% Non-GAAP”
GREEN DOT CORP reported the quarter ended December 31, 2025 results: revenue $522,615, net income $(46,823), EPS $(0.84).
“December 31, Year Ended December 31, 2025 2024 % Change 2025 2024 % Change (In thousands, except per share data and percentages) GAAP financial results Total operating revenues $ 522,615 $ 455,024 15% $ 2,080,491 $ 1,723,876 21% Net (loss) income $ (46,823) $ 5,103 * $ (98,866) $ (26,702) 270% Diluted (loss) income per common share $ (0.84) $ 0.09 * $ (1.79) $”
KALTURA INC reported the full year ended December 31, 2025 results: revenue $180.9 million.
“For the full year 2025, total revenue was $180.9 million, representing 1% year-over-year growth, and Adjusted EBITDA was $18.6 million, representing more than 150% year-over-year growth and materially exceeding the Company’s original annual guidance of approximately 100% growth.”
KALTURA INC reported the fourth quarter ended December 31, 2025 results: revenue $45.5 million, net income $0.6 million, EPS $0.00.
“Total revenue for the fourth quarter of 2025 was $45.5 million, almost flat compared to $45.6 million for the fourth quarter of 2024, and above the midpoint of the Company’s guidance range of $45.0 million to $45.7 million.”
HeartSciences Inc. reported fiscal third quarter ended January 31, 2026 results: revenue no meaningful revenue.
“HeartSciences reported no meaningful revenue for FQ3 2026”
Annovis Bio, Inc. reported financial results for the year ended December 31, 2025.
“On March 16, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the year ended December 31, 2025.”
CEA Industries Inc. reported third fiscal quarter ended January 31, 2026 results: net income $(106.6) million, EPS $(2.00).
“Fiscal Q3 2026 Net Income: $(106.6) million ● Fiscal Q3 2026 EPS: $(2.00)”
Townsquare Media, Inc. reported the year ended December 31, 2025 results: net income net loss of $9.8 million.
“Full Year Results* • As compared to the year ended December 31, 2024: • Net revenue decreased 5.2%, and 2.8% excluding political • Net loss decreased $1.2 million from a net loss of $10.9 million to a net loss of $9.8 million • Adjusted EBITDA decreased 12.2%, and 3.0% excluding political • Total Digital net revenue increased 0.9% • Digital Advertising net revenue increased 1.6% • Subscription Digital Marketing Solutions net revenue decreased 0.7% • Total Digital Segment Profit decreased 1.7% • Digital Advertising”
Townsquare Media, Inc. reported the fourth quarter ended December 31, 2025 results: net income net loss of $4.8 million, EPS $0.32.
“Fourth Quarter Results* • As compared to the fourth quarter of 2024: • Net revenue decreased 9.6%, and 4.5% excluding political • Net income decreased $29.8 million from net income of $25.0 million to a net loss of $4.8 million • Adjusted EBITDA decreased 30.9%, and 17.0% excluding political • Total Digital net revenue decreased 2.4% • Digital Advertising net revenue decreased 1.0% • Subscription Digital Marketing Solutions (“Townsquare Interactive”) net revenue decreased 5.6% • Total Digital Segment Profit decreased 14.8% • Digital Advertising Segment Profit decreased 28.0% • Subscription Digital Marketing Solutions Segment Profit increased 12.0% • Broadcast Advertising net revenue decreased 17.8%, and 7.9% excluding political • Net loss per diluted share was $0.32 and Adjusted Net Income per diluted share was $0.05 • Repaid $5.9 million of our Senior Secured Credit Facility, including $3.0 million of the Revolver and $2.9 million of Term Loan”
CytomX Therapeutics, Inc. reported the year ended December 31, 2025 results: revenue $76.2 million.
“Total revenue was $76.2 million for the year ended December 31, 2025, compared to $138.1 million in 2024.”
Silvercrest Asset Management Group Inc. reported the year ended December 31, 2025 results: revenue $125,319, net income $8,059, EPS $0.56 per basic and diluted share.
“For the Three Months Ended December 31, For the Twelve Months Ended December 31, (in thousands except as indicated) 2025 2024 2025 2024 Revenue $ 31,959 $ 31,962 $ 125,319 $ 123,651 (Loss) income before other income (expense), net $ (884 ) $ 1,957 $ 9,325 $ 17,627 Net (loss) income $ (107 ) $ 2,684 $ 8,059 $ 15,709 Net (loss) income margin (0.3 )% 8.4 % 6.4 % 12.7 % Net (loss) income attributable to Silvercrest $ (120 ) $ 1,618 $ 4,885 $ 9,535 Net (loss) income per basic share $ (0.01 ) $ 0.17 $ 0.56 $ 1.00 Net (loss) income per diluted share $ (0.01 ) $ 0.17 $ 0.56 $ 1.00”
Silvercrest Asset Management Group Inc. reported Fourth Quarter 2025 results: revenue $32.0 million, net income $0.1 million, EPS $0.01.
“Fourth Quarter 2025 Highlights • Total AUM of $37.0 billion, inclusive of discretionary AUM of $24.0 billion and non-discretionary AUM of $13.0 billion, at December 31, 2025. • Revenue of $32.0 million. • U.S. Generally Accepted Accounting Principles (“GAAP”) consolidated net loss and net loss attributable to Silvercrest of $0.1 million. • Basic and diluted net loss per share of $0.01.”
Tianci International, Inc. reported the fiscal quarter ended January 31, 2026 results: net income a net loss of $417,124.
“As a result, the Company incurred a net loss of $417,124 in the quarter ended January 31, 2026, an increased loss compared to the quarter ended January 31, 2025.”
Science Applications International Corp reported the full fiscal year ended January 30, 2026 results: revenue $7.26 billion, net income $358 million, EPS $7.70. Guidance initiated.
“• Q4 FY26 revenues of $1.75 billion; FY26 revenues of $7.26 billion • Q4 FY26 net income of $85 million, adjusted EBITDA (1) of $181 million or 10.3% of revenue; FY26 net income of $358 million, adjusted EBITDA (1) of $708 million or 9.7% of revenue • Q4 FY26 diluted earnings per share of $1.87, adjusted diluted earnings per share (1) of $2.62; FY26 diluted earnings per share of $7.70, adjusted diluted earnings per share (1) of $10.75”
Science Applications International Corp reported the fourth fiscal quarter ended January 30, 2026 results: revenue $1.75 billion, net income $85 million, EPS $1.87. Guidance initiated.
“• Q4 FY26 revenues of $1.75 billion; FY26 revenues of $7.26 billion • Q4 FY26 net income of $85 million, adjusted EBITDA (1) of $181 million or 10.3% of revenue; FY26 net income of $358 million, adjusted EBITDA (1) of $708 million or 9.7% of revenue • Q4 FY26 diluted earnings per share of $1.87, adjusted diluted earnings per share (1) of $2.62; FY26 diluted earnings per share of $7.70, adjusted diluted earnings per share (1) of $10.75”
Urgent.ly Inc. reported the three and twelve months ended December 31, 2025 results: revenue $33.3 million.
“partners and developing new customer partner opportunities, while continuing to deliver exceptional customer satisfaction scores.” Fourth Quarter 2025 Updates: • Revenue of $33.3 million, an increase of 4% year over year. • Gross profit of $8.7 million, an increase of 23% year over year. • Gross margin of 26% compared to 22% in the prior year period. • GAAP”
Atara Biotherapeutics, Inc. reported the fiscal year ended December 31, 2025 results: revenue $120.8 million, net income $32.7 million, EPS $2.61 per share. Guidance initiated.
“as compared to a net loss of ($12.7) million, or ($1.19) per share, and ($85.4) million, or ($11.41) per share, for the same periods in 2024. ● Commercialization revenues were $120.8 million in 2025 as compared to $128.9 million in 2024. ● Total costs and operating expenses include non-cash stock-based compensation, depreciation and amortization expenses of $1.6”
Atara Biotherapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: net income ($3.4) million, EPS ($0.25) per share. Guidance initiated.
“Atara reported a net loss of ($3.4) million, or ($0.25) per share, and a net income of $32.7 million, or $2.61 per share, for the fourth quarter and fiscal year 2025, respectively”
Cue Biopharma, Inc. reported the year ended December 31, 2025 results: revenue $27.5 million.
“The Company reported collaboration revenue of $27.5 million and $9.3 million for the years ended December 31, 2025 and 2024, respectively.”
Cue Biopharma, Inc. reported the three months ended December 31, 2025 results: revenue $21.9 million.
“The Company reported collaboration revenue of $21.9 million and $1.6 million for the three months ended December 31, 2025 and 2024, respectively.”
BEYOND MEAT, INC. reported the full year ended December 31, 2025 results: revenue approximately $275 million.
“Net revenues for the full year ended December 31, 2025 are expected to be approximately $275 million.”
BEYOND MEAT, INC. reported the fourth quarter ended December 31, 2025 results: revenue approximately $61 million. Guidance reaffirmed.
“Net revenues for the fourth quarter ended December 31, 2025 are expected to be approximately $61 million, which is in line with the Company’s previous guidance range of $60 million to $65 million.”
HF Foods Group Inc. reported Three Months Ended December 31, 2025 results: revenue $308,023, net income $(37,417), EPS $(0.70).
“Three Months Ended December 31, 2025 Change over Prior Year GAAP Measures Net revenue $ 1,228,282 $ 26,615 $ 308,023 $ 2,741 Gross profit $ 207,576 $ 2,382 $ 51,076 $ (1,079) Net loss $ (39,311) $ 8,791 $ (37,417) $ 6,524 Loss per share $ (0.73) $ 0.19 $ (0.70) $ 0.13”
HF Foods Group Inc. reported the year and quarter ended December 31, 2025 results: revenue $1,228,282, net income $(39,311), EPS $(0.73).
“thousands, except per share amounts) Year Ended December 31, 2025 Change over Prior Year Three Months Ended December 31, 2025 Change over Prior Year GAAP Measures Net revenue $ 1,228,282 $ 26,615 $ 308,023 $ 2,741 Gross profit $ 207,576 $ 2,382 $ 51,076 $ (1,079) Net loss $ (39,311) $ 8,791 $ (37,417) $ 6,524 Loss per share $ (0.73) $ 0.19 $ (0.70) $ 0.13 Non-GAAP”
Zomedica Corp. reported the year ended December 31, 2025 results: revenue $32.0 million, net income $81.9 million.
“(PRESS RELEASE) --- EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity Zomedica surpasses $10 million in quarterly revenue for the first time”
Zomedica Corp. reported the fourth quarter ended December 31, 2025 results: revenue $10.5 million.
“Revenue for the fourth quarter of 2025 grew 33% to $10.5 million”
Black Diamond Therapeutics, Inc. reported the year ended December 31, 2025 results: net income Net income for the year ended December 31, 2025 was $22.4 million compared to a net loss of $69.7 million for the year e.
“Net income for the year ended December 31, 2025 was $22.4 million compared to a net loss of $69.7 million for the year ended December 31, 2024.”
Black Diamond Therapeutics, Inc. reported the fourth quarter of 2025 results: net income Net loss for the fourth quarter of 2025 was $15.1 million.
“Net loss for the fourth quarter of 2025 was $15.1 million, as compared to $16.0 million for the same period in 2024.”
Rafael Holdings, Inc. reported the six months ended January 31, 2026 results: net income $16.2 million, EPS $0.32 per share.
“For the six months ended January 31, 2026, we recorded a net loss attributable to Rafael Holdings of $16.2 million, or $0.32 per share”
Rafael Holdings, Inc. reported the three months ended January 31, 2026 results: net income $6.4 million, EPS $0.13 per share.
“For the three months ended January 31, 2026, we recorded a net loss attributable to Rafael Holdings of $6.4 million, or $0.13 per share”
Olema Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the quarter and year ended December 31, 2025 was $46.1 million and $162.5 million, respectively.
“On March 16, 2026, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the year ended December 31, 2025.”
Microvast Holdings, Inc. updated its 2026 Outlook guidance (reaffirmed).
“While we are navigating evolving tariff structures and shifting regulatory and geopolitical events, we expect continued revenue growth in 2026”
Microvast Holdings, Inc. reported Fourth Quarter ended December 31, 2025 results: revenue Revenue of $96.4 million, net income Net profit of $16.5 million, EPS Net profit per share of $0.05.
“Revenue of $96.4 million, compared to $113.4 million in Q4 2024, a decrease of 15.0% as a result of regulatory shifts in South Korea and delays in customer platform ramp up in EMEA”
Microvast Holdings, Inc. reported Full Year ended December 31, 2025 results: revenue record $427.5 million, net income Net loss of $29.2 million, EPS Net loss per share of $0.09.
“Full Year revenue increased 12.6% year over year to a record $427.5 million • Full Year net loss of $29.2 million, compared to net loss of $195.5 million in 2024; Non-GAAP adjusted net profit of $13.0 million, compared to non-GAAP adjusted net loss of $84.6 million in 2024”
Aprea Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 16, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2025”
Playboy, Inc. reported full year ended December 31, 2025 results: revenue $120.9 million, net income $12.7 million.
“Full Year 2025 Financial Results Revenue increased to $120.9 million compared to $116.1 million in 2024, reflecting a year-over-year increase of $4.8 million, or 4%, primarily due to the continued strength of Playboy’s licensing business and higher Honey Birdette revenue. Operating expenses decreased to $129.0 million, as compared to $167.0 million in 2024, reflecting a year-over-year decrease of $38.0 million. The decrease was due primarily to a $22.0 million decrease in expenses related to the revamp of our digital businesses and lower non-cash asset impairment charges of $24.0 million, partly offset by higher severance of $1.8 million due to the reduction of headcount, a one-time settlement expense of $2.4 million and higher legal expenses and fees of $3.0 million due to additional litigation expenses. Net loss improved to $12.7 million, as compared to a net loss of $79.4 million in 2024.”
Playboy, Inc. reported fourth quarter ended December 31, 2025 results: revenue $34.9 million, net income $3.6 million, EPS $0.03 per share.
“Playboy Reports Fourth Quarter and Full Year 2025 Financial Results Q4 Revenue of $34.9 Million, Net Income of $3.6 Million & Adjusted EBITDA of $7.1 Million, or $8.0 Million Excluding Litigation Expenses”
Assertio Holdings, Inc. updated its the fiscal year ended December 31, 2025 guidance (initiated).
“Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Delivers FY2025 Net Product Sales and Adjusted EBITDA Above Guidance Expects Net Product Sales between $110M-$125M and Adjusted EBITDA between $28M-$40M in FY2026”
Assertio Holdings, Inc. reported financial results for the fourth quarter ended December 31, 2025.
“today reported financial results for the fourth quarter and full year ended December 31, 2025.”
AEye, Inc. reported the 2025 full year period results: revenue approximately $230,000, net income $(34.0) million, EPS $(1.47) per share. Guidance initiated.
“Full-year 2025 revenue totaled approximately $230,000, up 15% year over year.”
AEye, Inc. reported the year and quarter ended December 31, 2025 results: revenue approximately $100,000, net income $(7.3) million, EPS $(0.17) per share. Guidance reaffirmed.
“as we expect our technology lead will continue to translate into firm volume commitments and a durable revenue ramp.” Financial Highlights ● Q4 2025 revenue was approximately $100,000, a 94% quarterly sequential increase. Full-year 2025 revenue totaled approximately $230,000, up 15% year over year. ● Cash burn excluding net financing proceeds in Q4 2025 was $7.5”
DocGo Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $74.9 million, net income Net loss for the fourth quarter of 2025 was $142.3 million. Guidance raised.
“and operating results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights • Total revenue for the fourth quarter of 2025 was $74.9 million, compared to $120.8 million in the fourth quarter of 2024. This decline was entirely due to the wind-down of migrant-related programs, which generated $7.4 million of revenue in”
Eve Holding, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2025.
“On March 16, 2026, Eve Holding, Inc. (the “Company”) issued a press release announcing the Company’s results for its fourth quarter and fiscal year ended December 31, 2025.”
PLAYSTUDIOS, Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue $55.4 million, net income Net loss was $13.7 million.
“PLAYSTUDIOS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 RESULTS Fourth Quarter 2025 Revenue of $55.4 million”
Coya Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $21.2 million.
“Net loss was $21.2 million for the year ended December 31, 2025, compared to net loss of $14.9 million for the year ended December 31, 2024.”
OPAL Fuels Inc. reported financial results for the three and twelve months ended December 31, 2025.
“On March 16, 2026 , OPAL Fuels Inc. (the "Company") issued a press release regarding its financial results for the year ended December 31, 2025.”
Dragonfly Energy Holdings Corp. reported the full year ended December 31, 2025 results: revenue $58.6 million, net income $(69.9) million, EPS $(14.80) per diluted share. Guidance initiated.
“Net Sales increased 15.8% to $58.6 million. OEM net sales increased 33.8%, led by increased product adoption and new customer acquisitions . DTC net sales declined to $20.7 million, from $22.6 million, reflecting continued softness in the RV market due to continued macroeconomic pressures. Gross Profit increased 34.6% to $15.6 million and gross margin expanded 370 basis points to 26.7%, reflecting higher sales volumes. Operating Expenses were $(38.8) million, compared to $(37.4) million. The Company reported a Net Loss of $(69.9) million, or $(14.80) per diluted share, compared to a Net Loss of $(40.6) million or $(59.15) per diluted share.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.